NASDAQ · SURGICAL & MEDICAL INSTRUMENTS & APPARATUS · SMALL CAP
Work Medical Technology Group Ltd. WOK
4 fiscal years on record · USD · FY2025 reported · SEC filings only
Growth
USD 9.8M
Revenue, FY2025 · full 4-year series below
Revenue $M
Net income $M
FY2025 · Revenue 9.8 · Net income -1.1
Compound annual growth
Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.
Profitability
−12 cents
lost on every revenue dollar
Operating margin
Net margin
FY2025 · Operating -11.0% · Net -12.2%
ROE
FY2025 · ROE -6.8%
Each USD of equity lost 7 cents this year.
The 4-year record
4 fiscal years
Every figure from documents filed with the SEC · USD
EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.
row low → row highnegative
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Revenue $B | 0.0 | 0.0 | 0.0 | 0.0 |
| Operating income $B | −0.0 | −0.0 | 0.0 | 0.0 |
| EBITDA $B | −0.0 | −0.0 | 0.0 | 0.0 |
| Income tax $B | 0.0 | −0.0 | 0.0 | 0.0 |
| Net income $B | −0.0 | −0.0 | 0.0 | 0.0 |
| Free cash flow $B | 0.0 | −0.0 | 0.0 | −0.0 |
| EPS, diluted $ | −0.04 | −0.27 | 0.01 | 0.07 |
| Dividend / sh $ | · | · | · | · |
| Payout % | · | · | · | · |
| ROE % | −6.8 | −30.3 | 1.1 | · |
| Shares out B | · | 0.01 | 0.01 | · |
Slide the table for earlier years · "·" marks a figure not available in our data for that year.
Provenance
Company facts, as filed
How we verify · 0 failures in 14 reconciliationsAUDITED
Reconciled in 4 of 19 fiscal years. 62 checks could not be computed.
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivitySurgical & Medical Instruments & Apparatus
Listed onNASDAQ
Incorporated inoutside the United States — SEC code F4
Fiscal year endsSeptember 30
SEC categoryemerging growth company
Data on record since2022